When does rexulti patent expire?

When Does Rexulti Patent Expire?

Rexulti, also known as brexpiprazole, is an atypical antipsychotic medication approved for the treatment of schizophrenia and as an adjunct to antidepressants in adults with major depressive disorder.

What Happened to the Original Rexulti Patent?

The original patent for Rexulti expired in 2021 [1]. However, as with many pharmaceuticals, the manufacturer, Otsuka Pharmaceuticals, has obtained additional patents to extend exclusivity for specific uses or formulations of the medication.

Extended Exclusivity for Rexulti

According to DrugPatentWatch.com [2], Otsuka Pharmaceuticals has obtained several patents that extend exclusivity for Rexulti beyond the original patent expiration date of 2021. These include patents for specific formulations, dosages, and uses of the medication.

Timeline of Exclusivity Expiration for Rexulti

Here is a rough estimate of when the extended exclusivity for Rexulti is set to expire:

- The last patent expiration date for Rexulti is listed as October 1, 2032, by DrugPatentWatch.com [2], subject to potential changes in patent law.
- However, biosimilars may be approved before or shortly after the patent expires.
- When exclusivity expires, other companies will be able to market and sell generic or biosimilar versions of Rexulti, typically at a lower cost.

Keep in mind that patent expiration dates are subject to change, and this information is provided as a general guideline.

Sources:

[1] www.uspto.gov - U.S. Patent and Trademark Office

[2] www.drugpatentwatch.com - Rexulti patent data and expiration dates